Sponsored by ExoCM | March 13–14, 2026 | AVA Resort Cancún
Cancún, Mexico — The International Society for Stem Cell Application (ISSCA) is set to bring one of the most anticipated regenerative medicine events of the year to Latin America: the ISSCA Exosome Conference, taking place March 13–14, 2026, at the AVA Resort Cancún. Sponsored by ExoCM, the conference will gather global leaders, pioneering researchers, and front-line clinicians to explore the future of exosome-based therapies and their projected impact on modern healthcare.
As exosomes rapidly emerge as one of the most innovative tools in cellular communication and tissue regeneration, ISSCA’s mission is to empower physicians with next-generation education, global standards, and clinically applicable knowledge. This conference is expected to accelerate the adoption of advanced regenerative technologies across Latin America and beyond, positioning the region as a growing hub for medical innovation.
“Exosomes are redefining what is possible in regenerative medicine,” said Benito Novas, Founder of ISSCA.
“Our goal with this conference is to provide physicians worldwide with access to the most advanced insights, real clinical protocols, and visionary leaders shaping the next era of cell-free therapeutics. ISSCA remains committed to delivering education that transforms medical practice and expands global health possibilities.”
A Gathering of Global Thought Leaders
The conference will feature a distinguished international faculty presenting the expected future impact of exosome-based therapies across fields such as aesthetics, longevity, immunomodulation, metabolism, and musculoskeletal repair:
- Benito Novas (USA) – Global Leadership in Cellular Therapies & ISSCA Strategic Vision
- Dr. Rafael Gonzalez (USA) – Clinical-Grade Secretomes as the Future of Medicine
- Dr. Keith L. March (USA) – Exosomes + MSCs: Emerging Mechanisms & Therapeutic Potential
- Dr. Alan Gaveck (USA) – Preclinical Validation & Protocol Development
- Dr. Andrea Lapeire (Argentina) – Functional Restoration, Longevity & Metabolic Modulation
- Dr. Richard Silva, DO (USA) – Future Innovations in MSK Repair
- Prof. Dr. Roni Moya (Portugal) – Regenerative Aesthetics & Tissue Optimization
- Dr. Marcio Kume, PhD (Brazil) – Musculoskeletal Regeneration & Combination Cellular Strategies
- Dr. Shino Bay Aguilera (USA) – Exosomes + Peptides as the Next Frontier in Non-Invasive Rejuvenation
- Dr. Wajid Burad (Mexico) – Functional Recovery, Performance & Cellular Optimization
AGENDA ISSCA EXOSOME CONFERENCE
Experts will share forward-looking insights on the projected role of exosomes in tissue repair, aging reversal, precision medicine, and metabolic health—topics expected to shape the next decade of regenerative therapeutics.
Clinical Certifications: Expanding Physician Capabilities Worldwide
ISSCA will offer two specialized clinical certifications expected to expand the skillset of physicians integrating exosome-based therapies into their practice:
1. Regenerative Aesthetics with Exosomes
Training designed to master exosome-based facial and aesthetic regeneration using advanced tools such as PRP, plasma gel, PDO threads, nanoneedling, and biostimulation peptides.
2. Regenerative Medicine & Exosomes
A clinically structured certification expected to provide the framework for applying exosomes in metabolic recovery, immunity, longevity, gut health, and IV therapy integration.
These programs reflect ISSCA’s commitment to standardized education, global clinical excellence, and safe application of emerging biologics.
MedConnect: A Global Networking Experience
ISSCA will also host MedConnect, a signature networking gathering that encourages collaboration among clinicians, researchers, and medical innovators. Participants can expect a vibrant environment designed to spark partnerships and advance the global regenerative.
“ISSCA’s training elevated my practice to a new level. Their programs are the most complete and clinically useful in the field.”
— Dr. J. Hernández, Colombia
“The level of expertise and hands-on structure provided by ISSCA is unmatched.”
— Dr. L. Afonso, Brazil
Physicians and healthcare professionals interested in attending can now secure their place.
👉 Register Now
www.issca.com
Exclusive benefits include:
- Early-bird pricing
- Priority access to certification seats
- Invitation to the MedConnect networking event
- Access to pre-event webinars and educational resources
About ISSCA
“The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.”
About Global Stem Cells Group
“Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.”
Safe Harbor Statement
Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business, partly based on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
